Research & References
The published studies on X39 and the patent behind the technology, gathered in one place. Read them in full and form your own view.
In the interest of transparency: the X39 studies below were carried out by researchers associated with LifeWave and published in open-access journals. We’ve linked each original source alongside a copy here, so you can review every study — its methods, sample size and funding — in full, and judge the evidence for yourself.
Double-Blind Testing of the LifeWave X39 Patch to Determine GHK-Cu Production Levels
Connor CA, Connor MH, Yue D, Eickhoff J, Wagner S, Chang A · Internal Medicine Research – Open Journal, Vol 6(1), 2021 · Randomised, double-blind controlled trial (n = 60)
Read the PDFPhototherapy Induced Metabolism Change Produced by the LifeWave X39 Non-transdermal Patch
Connor MH, Connor CA, Gombusuren N, Eickhoff J, Anderson N, Perry M, Peugh L · International Journal of Research Studies in Medical and Health Sciences, Vol 6(5), 2021 · Randomised, double-blind controlled trial (n = 50)
Read the PDFLifeWave X39 Pilot Demonstrates Light Triggered Changes
Connor MH, Connor CA, Gombosuren N, Eickhoff J, Pugh L · International Journal of Healing and Caring, Vol 20(2), 2020 · Pilot study (n = 15)
Read the PDFWearable Phototherapy Apparatus with Anti-Viral and Other Effects
US Patent 10,898,724 B2 · Inventor: David Schmidt · Assignee: Soletluna Holdings, Inc. (LifeWave) · Granted 26 January 2021
Read the PDF← Back to The Science · or Learn about X39
These materials are provided for information and transparency. X39 is a general wellness product. The studies and patent linked here reflect their authors’ and LifeWave’s own statements and have not been evaluated by the FDA or the TGA. X39 is not intended to diagnose, treat, cure or prevent any disease.